Carcinomatous Meningitis From Urothelial Carcinoma of Bladder and Ureter: Case Report

Matsushita, Mabumi; Kawasaki, Yoshihide; Okada, Yasuhiro

doi:10.5980/jpnjurol1989.95.817

Cited by 3 publications

(3 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The literature includes 22 cases of MC secondary to bladder cancer (Table 1) [5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20] . Four of these 22 cases presented with MC and the bladder primary was later diagnosed.…”

Section: Discussionmentioning

confidence: 99%

Meningeal Carcinomatosis: An Extremely Rare Involvement of Urinary Bladder Carcinoma

Uncu

Arpacı

Beyzadeoğlu

et al. 2010

Tumori

View full text Add to dashboard Cite

Meningeal carcinomatosis (MC) is a rare presentation of solid tumors, particularly breast cancer, lung cancer, and malignant melanoma. Recently, the incidence of MC has been reported to be increasing. It has a bad prognosis despite aggressive therapy. The usual clinical presentation is multifocal involvement of the neuraxis, with headache and radicular pain being the most common initial symptoms. The most frequent signs are motor deficits, altered mental status, and cranial nerve involvement. The treatment of MC remains controversial and no straightforward guidelines exist in the literature. MC from urinary bladder tumors is rare. In this case report, we present a 52-year-old male patient with meningeal metastasis from a primary urinary bladder carcinoma along with a review of the related literature. Free full text available at www.tumorionline.it

show abstract

Section: Discussionmentioning

confidence: 99%

Meningeal Carcinomatosis: An Extremely Rare Involvement of Urinary Bladder Carcinoma

Uncu

Arpacı

Beyzadeoğlu

et al. 2010

Tumori

View full text Add to dashboard Cite

show abstract

“…For example, Bishop et al [7] reported 2 patients developing disease after systemic treatment with MTX, vinblastine, Adriamycin, and cisplatin (MVAC). Matsushita et al [8] reported a case occurring 16 months after their patient had had a complete response following chemotherapy and surgery, and Boukriche et al [9] reported a case occurring 4 years after adjuvant treatment for resected bladder cancer. Still, just as many cases present concurrently with widespread systemic disease, suggesting that TCC may have an affinity for the CNS and that carcinomatous meningitis may be more common than realized.…”

Section: Discussionmentioning

confidence: 99%

Carcinomatous Meningitis: The Natural History of Successfully Treated Metastatic Bladder Cancer

Tadepalli

Coleman²,

Hacket³

et al. 2011

Case Rep Oncol

View full text Add to dashboard Cite

Carcinomatous meningitis due to bladder cancer is a rare entity reported only in case reports. Optimal therapy is thus poorly defined with earlier cases reporting an unsuccessful outcome. Here we report a case of late carcinomatous meningitis secondary to transitional cell carcinoma (TCC) of the bladder occurring in a patient in complete remission. He was successfully treated with intrathecal methotrexate and whole brain irradiation and experienced prolonged survival after treatment. With modern chemotherapy increasing complete remissions and survival rates in patients with TCC, more and more patients are being reported with carcinomatous meningitis. We raise the question of whether central nervous system prophylaxis should be considered in patients with TCC achieving a complete remission to chemotherapy in the metastatic setting.

show abstract

“…Carcinomatous meningitis is rare in bladder cancer [14]-[16]. Trastuzumab does not cross the blood–brain barrier [17], suggesting that targeting Her2/ neu positive systemic disease may alter the natural history of bladder carcinoma metastasis predisposing to the onset and progression of central nervous system (CNS) disease.…”

Section: Discussionmentioning

confidence: 99%

Carcinomatous meningitis in a patient with Her2/neu expressing bladder cancer following trastuzumab and chemotherapy: a case report and review of the literature

et al. 2009

View full text Add to dashboard Cite

IntroductionTargeted therapies may impact the natural history of bladder cancer based upon their pharmacokinetics. The Her2/neu receptor tyrosine kinase, overexpressed by half of all primary urothelial carcinomas, has recently been examined as a therapeutic target in bladder cancer in a prospective phase II multicenter trial (NCI-198) that enrolled 109 patients with advanced bladder carcinomas for treatment with trastuzumab in combination with paclitaxel, carboplatin, and gemcitabine. We report on documented isolated Her2/neu positive carcinomatous meningitis in a patient treated with trastuzumab.Case presentationA 61-year-old Caucasian man with metastatic bladder cancer was treated with neoadjuvant chemotherapy in combination with trastuzumab with a partial response that was followed by a complete response after surgery. He relapsed with isolated Her2/neu positive carcinomatous meningitis.ConclusionCarcinomatous meningitis in bladder cancer is extremely rare. This is the first case reported of Her2/neu positive carcinomatous meningitis. Disease recurred solely at a sanctuary site, demonstrating that despite the systemic efficacy of trastuzumab in combination with chemotherapy, its inability to enter the central nervous system potentially contributes to the unusual site of disease recurrence.

show abstract

Carcinomatous Meningitis From Urothelial Carcinoma of Bladder and Ureter: Case Report

Cited by 3 publications

References 5 publications

Meningeal Carcinomatosis: An Extremely Rare Involvement of Urinary Bladder Carcinoma

Meningeal Carcinomatosis: An Extremely Rare Involvement of Urinary Bladder Carcinoma

Carcinomatous Meningitis: The Natural History of Successfully Treated Metastatic Bladder Cancer

Carcinomatous meningitis in a patient with Her2/neu expressing bladder cancer following trastuzumab and chemotherapy: a case report and review of the literature

Contact Info

Product

Resources

About